Top 5 IBD 50 Drug Stocks Thriving Via Acquisitions

By | March 7, 2015

Scalper1 News

The recent flurry of deal-making in the drug sector has put the spotlight on other top-rated drugmakers that have grown with the help of savvy mergers and acquisitions. In just the past week, AbbVie (ABBV) agreed to buy Pharmacyclics (PCYC) for $21 billion, beating out Johnson & Johnson (JNJ), and Mallinckrodt (MNK) announced a $2.3 billion deal to acquire privately held Ikaria. The latest IBD 50 includes five drugmakers that are growing quickly Scalper1 News

Scalper1 News